- March 8, 2021
On March 8, 2021, FDA hosted a virtual public meeting on Patient-Focused Drug Development for Vitiligo. FDA was interested in hearing patients’ perspectives on the impact of vitiligo on daily life and patient views on treatment approaches.
March 8, 2021
10:00 a.m. - 2:30 p.m. EST
In addition to providing input at the public meeting, stakeholders are invited to provide their perspectives on the discussion questions through the public docket.
- The docket closes on May 10, 2021. FDA is interested in responses to the questions listed in the public docket.
|Virtual Public Meeting on Patient-Focused Drug Development for Vitiligo||pdf (144.91 KB)|
|Vitiligo PFDD Meeting Slides Final||pdf (1.70 MB)|
|FDA Public Meeting on Patient Focused Drug Development for Vitiligo Transcript||pdf (8.94 MB)|